Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface

Dodd, Stephanie and Kollipara, Sivacharan and Heimbach, Tycho and Beato, Stefania and Sanchez-Felix, Manuel and Meng, Qingshuo (2019) Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface. Journal of Pharmaceutical Sciences, 108 (1). pp. 87-101. ISSN 15206017

Abstract

Advances in understanding of human disease have prompted the U.S. Food and Drug Administration to classify certain molecules as “break-through therapies,” providing an accelerated review that may potentially enhance the quality of patient lives. With this designation come compressed timelines to develop drug products, which are not only suitable for clinic trials but can also be approved and brought to the market rapidly. Early risk identification for decreased oral absorption due to drug-drug interactions with proton pump inhibitors (PPIs) or acid-reducing agents (ARAs) is paramount to an effective drug product development strategy. An early ARA/PPI drug-drug interaction (DDI) risk identification strategy has been developed using physiologically based absorption modeling that readily integrates ADMET predictor generated in silico estimates or measured in vitro solubility, permeability, and ionization constants. Observed or predicted pH-solubility profile data along with pKas and drug dosing parameters were used to calculate a fraction of drug absorbed ratio in absence and presence of ARAs/PPIs. An integrated physiologically based pharmacokinetic absorption model using GastroPlus™ with pKa values fitted to measured pH-solubility profile data along with measured permeability data correctly identified the observed ARA/PPI DDI for 78% (16/22) of the clinical studies. Formulation strategies for compounds with an anticipated pH-mediated DDI risk are presented.

Item Type: Article
Keywords: absorption computational ADME drug-drug interaction(s) formulation in silico modeling permeability pharmacokinetics physiologically based pharmacokinetic (PBPK) modeling solubility
Date Deposited: 16 Jan 2019 00:45
Last Modified: 16 Jan 2019 00:45
URI: https://oak.novartis.com/id/eprint/37227

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.